Journal of Applied Physiology Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

J Appl Physiol 82: 1826-1835, 1997;
8750-7587/97 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudolph, A. S.
Right arrow Articles by Feuerstein, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rudolph, A. S.
Right arrow Articles by Feuerstein, G.

Journal of Applied Physiology
Vol. 82, No. 6, pp. 1826-1835, June 1997
SYSTEMIC CIRCULATION AND FLUID BALANCE

Liposome encapsulation attenuates hemoglobin-induced vasoconstriction in rabbit arterial segments

Alan S. Rudolph1, Anthony Sulpizio2, Paul Hieble2, Victor Macdonald3, Mark Chavez3, and Giora Feuerstein2

1 Center for Bio/Molecular Science and Engineering, Naval Research Laboratory, Washington 20375-5348; 2 Department of Cardiovascular Pharmacology, SmithKline Beecham, King of Prussia, Pennsylvania 19406; and 3 Blood Research Detachment, Walter Reed Army Institute of Research, Washington, District of Columbia 20307

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
ACKNOWLEDGEMENTS
FOOTNOTES
REFERENCES

ABSTRACT

Rudolph, Alan S., Anthony Sulpizio, Paul Hieble, Victor Macdonald, Mark Chavez, and Giora Feuerstein. Liposome encapsulation attenuates hemoglobin-induced vasoconstriction in rabbit arterial segments. J. Appl. Physiol. 82(6): 1826-1835, 1997.---Free hemoglobin (Hb) induces a potent vasoconstrictor response that may limit its therapeutic application as a red blood cell replacement. We have investigated whether encapsulation of stroma-free Hb (SFHb) or cross-linked Hb (alpha alpha -Hb) in liposomes modulates Hb vasoactivity in isolated blood vessels. Relaxation of rabbit thoracic vessels was measured before and after exposure to acellular SFHb, alpha alpha -Hb, and liposome-encapsulated SFHb or alpha alpha -Hb. SFHb and alpha alpha -Hb caused significant inhibition of carbachol-induced relaxation at 0.5 mg/dl, whereas encapsulation inhibited vessel relaxation at 30- to 60-fold higher Hb concentrations. The contractile response of rabbit ear arterial segments to electrical stimulation in the presence of acellular alpha alpha -Hb resulted in a 150% increase (EC150) in contractile amplitude at 0.23 mg/dl, whereas the EC150 for encapsulated alpha alpha -Hb was 13.7 mg/dl. Mechanistic studies of the vasoconstrictor activity of Hb demonstrated that acellular alpha alpha -Hb had no effect on norepinephrine release in the rabbit ear artery. In addition, neither acellular nor encapsulated alpha alpha -Hb preparations inhibited endothelial nitric oxide (NO) synthase activity isolated from bovine pulmonary artery. However, inhibition of vessel relaxation by acellular or encapsulated alpha alpha -Hb was reversed by the NO donor S-nitrosylpenacillamine, implicating Hb-NO binding as a possible mechanism for the vasoconstrictor response. In vitro stopped-flow kinetic studies of Hb-NO binding showed similar rates of reaction for conversion of oxyhemoglobin to methemoglobin (metHb; <2 ms), followed by rapid conversion of metHb to NO-Hb (300 ms) for both acellular and encapsulated alpha alpha -Hb, demonstrating that liposome encapsulation does not retard NO-Hb binding. The attenuated vasoactivity of encapsulated Hb may, therefore, result from the limited access of encapsulated Hb to NO imposed by the physical size of the liposome and reduced penetration of Hb across the vascular endothelium.

nitric oxide; blood substitute

INTRODUCTION

THE SEARCH FOR A RED BLOOD CELL substitute remains driven by frequent shortages of blood in major urban centers, the logistics of providing blood for military medicine, and continuing public concern over the safety of the global blood supply (11). The development of chemically modified acellular hemoglobin (Hb) solutions as oxygen-carrying red blood cell substitutes has been hampered by a number of adverse reactions, including nephro- and neurotoxicity, mononuclear phagocytic system activation, and coagulation thrombosis after infusion in exchange-transfused and hemorrhagic-shock models (see Ref. 53 for review). Mild adverse reactions in human safety trials have slowed the progress toward use of a Hb-based red blood cell substitute in the clinic (27, 31, 45, 56).

There is a long and rich history of investigation into the vascular reactivity of Hb solutions. Early studies with transfusion of hemolysate preparations demonstrated in animals and humans a rebound hypertension that persisted for as long as 2-3 h after transfusion (2, 3, 30). This effect was also observed in purified Hb preparations in normovolemic, exchange-transfused, or hemorrhaged animals with increases in mean arterial pressure 20-40 mmHg over that expected by a simple volume replacement (18, 36, 50). The hypertensive response elicited by infusion of acellular Hb is associated with reduced cardiac output and increased systemic and pulmonary vascular resistance (3, 36, 50). Although isolated vascular segments provide limited information wth regard to complex systemic vascular responses, these models have proved useful in discerning possible mechanisms of Hb-induced vascular reactivity. The vasoconstrictor activity of acellular Hb solutions has been demonstrated in isolated organs, vascular segments, and microvascular beds in situ at pharmacological doses (8, 15, 24, 26, 52). Regional blood flow studies after stroma-free Hb (SFHb) administration have shown increased blood flow to the heart, brain, liver, gut, and kidneys in the dog (34). These findings were recently confirmed in the rat with the use of a chemically cross-linked acellular Hb (alpha alpha -Hb) preparation (47). It has been suggested by these investigators that the hypertensive response of acellular chemically modified Hb is thus manifested by a redistribution of blood flow. Administration of acellular Hb in humans has also resulted in increased mean arterial pressure. This hypertensive response may be related to observations of gastrointestinal vasoconstriction that have been suggested to cause the esophageal peristalsis, abdominal cramping, nausea, and vomiting observed in healthy normal volunteers (4, 33).

One strategy that has been explored in the effort to deliver Hb as an oxygen-carrying resuscitative fluid is to encapsulate the protein in liposomes (7, 10, 12, 20). Encapsulation of Hb has been demonstrated to increase circulation persistence, reduce kidney distribution, and enable freeze-dried preservation for long-term storage (43, 44). Early preparations of encapsulated bovine Hb induced a transient hypertension and reduced cardiac output with increased heart rate and total peripheral resistance index after administration in normovolemic rats (37). These effects were shown to correlate with the soybean-based lipid components of the liposome vehicle that included contaminating lysolecithin and may have involved a direct vasoconstrictor response induced by increased thromboxane A2 and platelet-activating factor (38, 41). Modifying the lipid components of the liposome to include a synthetic distearoylphosphatidylcholine (instead of the soy-based lecithin) was shown to alleviate some of these untoward hemodynamic responses. Encapsulated-Hb preparations used in exchange transfusion in rats and rabbits showed a return to basal mean arterial pressure with no rebound hypertension observed (16, 39, 40). Administration of liposome-encapsulated Hb with hypertonic saline in a hemorrhagic shock model in the rat also decreased mortality and improved tissue oxygenation, with rapid recovery of basal mean arterial pressure (40).

In these studies, we present the first examination of the vasoactivity of encapsulated Hb in isolated vascular segments. Using the rabbit aorta preparation, we investigated the effect of free and encapsulated Hb (chemically modified by intramolecular cross-linking and native SFHb) on the vasorelaxation produced by endogenous or exogenous sources of nitric oxide (NO). Using the isolated rabbit ear artery preparation, we quantified the effect of free and encapsulated alpha alpha -Hb on electrical stimulation-induced vasoconstriction. Additionally, we correlated the vasoactivity of encapsulated and acellular Hb to the kinetics of NO-Hb binding in encapsulated and acellular forms determined by in vitro stopped-flow kinetic studies.

MATERIALS AND METHODS

SFHb, alpha alpha -Hb [Hb cross-linked at Lys99 between the alpha -subunits with bis(3,5-dibromosalicyl)fumarate] were obtained from pilot plant production by the Blood Detachment of the US Army (54). After production, the following alpha alpha -Hb characteristics were measured: methemoglobin (metHb) = 4.7%, oxygen-carrying capacity (P50) = 21.5 Torr, phospholipids <0.1 µg/ml, endotoxin = 0.125 endotoxin units/ml, and free iron = 1.93 × 10-6 mol Fe/mol heme. The material passed both US sterility and rabbit-pyrogen testing. SFHb characteristics were similar, with the exception of P50 (5.2 Torr) and metHb (0.5%). Liposome-encapsulated Hb preparations were prepared as previously described (44). Briefly, lipid components distearoylphosphatidylcholine, dimyristoyl phosphatidylglycerol (Avanti Polar Lipids, Birmingham, AL), cholesterol (Cal Biochem, San Diego, CA), and alpha -tocopherol (Sigma Chemical, St. Louis, MO), in a 10:9:0.9:0.1 mol ratio, were dissolved in chloroform, and the solvent was then evaporated under vacuum. The film was then hydrated with sterile water and lyophilized to a powder. The freeze-dried powder was hydrated with either SFHb or alpha alpha -Hb (14 g/dl). The multilamellar liposome-encapsulated Hb solutions were processed with a high-shear apparatus (Microfluidics, Boston, MA) to form unilamellar vesicles. Vesicle size was measured by photon-correlation spectroscopy (Coulter Electronics, Norwalk, CT). Unencapsulated Hb was removed by tangential-flow filtration, using 300-kDa cutoff polysulfone filters (Millipore, Boston, MA). The washed liposome-encapsulated Hb preparations were then suspended in modified Dulbecco's phosphate-buffered saline to 35% by volume. Liposome vehicles without Hb were prepared in the same fashion, with the replacement of modified Dulbecco's phosphate-buffered saline for Hb. Endotoxin levels of all acellular and encapsulated Hb preparations were measured by using a chromophore-based Limulus amebocyte lysate test that was read at 580 nm (Cape Cod Associates).

New Zealand White rabbits (2-3 kg) were killed by pentobarbital sodium overdose administered intravenously in the ear vein (according to the Guide for Care and Use of Laboratory Animals, DHHS Publ. No. 86-23). The thoracic aorta was rapidly excised and dissected free of adhering connective tissue and fat. The isolated aortas were cut into ring segments ~3- to 4-mm wide and suspended, via two tungsten wire (0.008-in. diameter) hangers positioned in the lumen of each segment, in 50-ml organ baths containing Krebs-Henseleit solution having the following composition (in mM): 119 NaCl, 4.7 KCl, 1.2 KH2PO4, 2.5 CaCl, 25 NaHCO3, and 11 glucose. The baths were maintained at 37°C and aerated continuously with 95% O2-5% CO2.

A resting tension of 2 g was applied to each segment, and the tissues were equilibrated under these conditions for 45-60 min before testing. Isometric tensions were measured by using a force-displacement transducer (Grass FT03c) and recorded on a physiograph (Narcotrace 80). A concentration-response curve to norepineprine was performed in all tissues to assist in the selection of a submaximal contractile concentration of norepinephrine to be used for the relaxation studies. It was determined that concentrations of 0.1-0.2 µM produced a submaximal (50-70%) contraction of these aortic tissues. The tissues were then exposed to the appropriate concentration of norepinephrine. After the contraction stabilized, the ability of the tissues to relax to NO was determined by exposing the tissues to increasing concentrations (10-7 to 10-5 M) of carbachol (a cholinergic agonist that promotes the endogenous release of NO) until no further relaxation could be obtained. At the completion of the carbachol concentration-response curve, the norepinephrine and carbachol were removed from the bath by rinsing several times with Krebs-Henseleit buffer, and the baseline tension was readjusted to 2 g. The tissues were then exposed to SFHb, alpha alpha -Hb, liposome-encapsulated SFHb, or alpha alpha -Hb over an equivalent milligram Hb dose range. Thirty minutes later, the carbachol-induced relaxation was repeated, as described above, in the presence of the Hb preparation. The relaxation response at each carbachol concentration is expressed as a percent reduction in the norepinephrine-induced contraction.

The isolated perfused rabbit ear artery preparation used in these studies was modified from a previously described method (49). Male New Zealand White rabbits (3-5 kg) were killed by pentobarbital sodium overdose administered intravenously via the marginal ear vein. The ears were removed, and a 3- to 5-cm portion of the central ear artery was dissected from the base of the ear and immediately placed in Krebs-Henseleit solution. With the aid of a dissecting microscope, the artery was cannulated at both ends with polyethylene tubing (Intramedic PE-50). The tubing was secured at each end of the artery with two ties of 4-0 surgical sutures. The cannulated artery was mounted in a tubular glass chamber and simultaneously perfused intraluminally and superfused extraluminally with Krebs-Henseleit buffer by using a Gilson Minipulse 2 multichannel pump. At the pump setting used in these studies, the resultant flow rate was 2.6 and 1.3 ml/min for the intraluminal and superfusion circuits, respectively. The intraluminal perfusion pressure was measured with a pressure transducer (Statham, P23A) and recorded on a physiograph (Narco Biosystems).

All Hb preparations were delivered to the tissue via the intraluminal flow. The Krebs-Henseleit reservoir was aerated continuously with a 95% O2-5% CO2 mixture and was maintained at 37°C. The artery was equilibrated under these conditions for ~20 min, during which time perfusion pressure stabilized at 15-25 mmHg. The artery was then challenged with a 1 µM concentration of norepinephrine via the intraluminal flow to determine the responsiveness of the artery to a contractile agent and to replenish the sympathetic nerve terminals. After this challenge, the norepinephrine was removed from the perfusion flow. When perfusion pressure returned to baseline, cocaine (final concentration at the artery = 1 µM) was added to the Krebs-Henseleit reservoir to augment the contractile response to electrical stimulation by inhibiting the uptake of neuronally released norepinephrine.

The periarterial sympathetic nerves were stimulated electrically through platinum electrodes located at both ends of the glass chamber to elicit a contractile response. The stimulation consisted of a 0.5-s train of 0.7-ms-duration square-wave pulses at a frequency of 10 Hz and supramaximal voltage (90-100 V). This stimulus was applied at 4-min intervals, as we have found that this cycle does not fatigue the tissues, provides a consistent contractile amplitude that can be maintained for several hours, and there is a 1-min lag time before the test solutions reach the tissue. The amplitude of the contractile response to electrical stimulation stabilized within 60 min and typically produced a peak increase of 30-50 mmHg over baseline perfusion pressure. When the contractile response to electrical stimulation stabilized, increasing concentrations of the Hb preparations were delivered to the artery via the intraluminal flow. The artery was exposed to each concentration of the acellular- or encapsulated-Hb preparation for two cycles of stimulation, because it was found that the peak effect of Hb exposure occurred within 8 min of exposure (2 stimulation cycles), and no additional effect was obtained by using a 12-min (3 stimulation cycles) exposure. Thus, all changes from baseline produced by individual Hb concentrations were calculated by using the response produced at the second stimulation. The change in contractile amplitude produced by each Hb preparation was expressed as a percent increase over baseline (i.e., response immediately preceding the introduction of Hb) amplitude.

Statistical significance of the vasoactivity of Hb and liposome-encapsulated Hb in the two models was evaluated with the Student-Newman-Keuls test. Statistical significance of varying concentrations of Hb or encapsulated Hb were calculated at maximal relaxation in the rabbit aortic segments. The 150% effective concentration (EC150) values in the electrically stimulated ear artery model for the two preparations were also evaluated and are noted in the text.

To determine the effect of acellular Hb on norepinephrine release, ear arteries were incubated for 30 min in Krebs-Henseleit buffer maintained at 37°C that contained 20 µCi of [3H]norepinephrine (sp. act., 55.5 Ci/mmol; New England Nuclear, Boston, MA). After the incubation period, the vessels were mounted in the perfusion chambers, as described above, and perfused/superfused for 2 h to remove any [3H]norepinephrine that might have bound to the surface of the blood vessel. [3H]norepinephrine release was induced at 20-min intervals by exciting the periarterial adrenergic nerves via a 2-min electrical stimulation consisting of square-wave pulses of 0.7- ms duration at 2-Hz frequency and supramaximal voltage. The superfusate was collected for 2 min before each stimulation to determine basal [3H]norepinephrine release and again during the stimulation period to determine stimulated [3H]norepinephrine release. Rauwolscine (100 nM, Carl Roth, Karlsruag, Germany), an alpha -adrenoceptor antagonist that enhances norepinephrine release by blocking the inhibitory alpha 2-adrenoceptor located on the nerve terminal, was examined as a positive control for [3H]norepinephrine release. Each superfusate sample was mixed with 16 ml of Ready Safe scintillation cocktail (Beckman Instruments, Fullerton, CA) and counted on a beta-scintillation counter. Release was expressed as the ratio between 3H release during stimulation divided by 3H release during the preceding basal sample.

Endothelial NO synthase (eNOS) activity was determined by using enzyme isolated from the solubilized microsomal fraction from bovine pulmonary artery endothelial cells grown to confluence in culture (6). The assay measured the formation of [3H]citrulline, a by-product of NO synthesis, from [3H]arginine with the use of ion-exchange chromatography to separate the negatively charged arginine from the uncharged citrulline molecules. The effect of each concentration of the Hb preparations on eNOS activity was examined as a percent inhibition of [3H]citrulline production.

Reaction kinetics of alpha alpha -Hb and liposome-encapsulated alpha alpha -Hb binding with NO were initiated by combining 0.1 M phosphate buffer (pH 7.2, 24°C, purged with N2, and equilibrated with NO) with the same buffer equilibrated with room air containing either alpha alpha -Hb or liposome-encapsulated alpha alpha -Hb. Rapid mixing (2 ms) into a spectral flow cell was accomplished with a dual-syringe stopped-flow apparatus connected to a rapid-scanning spectrophotometer (RSM-1000 Stopped-Flow; On-Line Instrument Services, Bogart, GA) (35). Spectral scans from 485.3 to 715.3 nm in 1.15-nm steps were collected at a rate of 1,000/s. The final concentration of reactants in the flow cell was as follows: NO concentration ([NO]) = 0.96 mM; alpha alpha -Hb heme concentration ([heme]) = 42 µM; liposome-encapsulated alpha alpha -Hb [heme] = 6.9 µM (17.8 M intraliposomal). Optical scattering with liposome-encapsulated alpha alpha -Hb required averaging over 16 ms to increase the signal-to-noise ratio of the spectral data set. All data were analyzed with the GFIT global analysis program (28).

RESULTS

Vasorelaxation of precontracted rabbit thoracic aorta segments. A typical physiograph recording of the vasodilatory response to carbachol in aortic segments precontracted with norepinephrine is shown in Fig. 1A. The relaxation to carbachol is markedly inhibited in the presence of a pharmacological dose (2.5 mg/dl) of acellular alpha alpha -Hb. The same concentration of encapsulated alpha alpha -Hb had essentially no effect on the relaxation response. The inhibition of relaxation by acellular alpha alpha -Hb was concentration dependent, with significant inhibitions of 27 (P < 0.001), 67 (P < 0.001), and 89% (P < 0.001) compared with the maximum response to carbachol produced at concentrations of 0.5, 2.5, and 5.0 mg/dl, respectively (Fig. 2). From this data, the concentration of acellular alpha alpha -Hb required to produce a 50% effective concentration (EC50) of the carbachol maximum was calculated to be 1.6 mg/dl. Acellular SFHb possessed a profile of inhibition similar to acellular alpha alpha -Hb. Concentrations of 0.5, 1.0, 2.5, and 5.0 mg/dl of acellular SFHb produced statistically significant inhibitions of 15 (P < 0.05), 32 (P < 0.05), 51 (P < 0.001), and 84% (P < 0.001), respectively, compared with the maximum control carbachol relaxation (Fig. 3). The EC50 calculated from these data for acellular SFHb was 2.4 mg/dl. These results indicate that the two acellular Hb preparations possess very similar potency in inhibiting NO-mediated vascular relaxation in this model.
Fig. 1. Tensiograms of constriction-relaxation cycle or rabbit thoracic aortas in presence of free and encapsulated hemoglobin (Hb). Aortas are precontracted with 10-7 M norepinephrine and relaxed with increasing concentration of carbachol (A). Relaxation of vessel is completely inhibited by treatment with 2.5 mg/dl acellular (cross-linked) alpha alpha -Hb (C), while treatement with 2.5 mg/dl encapsulated alpha alpha -Hb showed much attenuated inhibition of carbachol-induced relaxation (B).
[View Larger Version of this Image (13K GIF file)]

Fig. 2. Effect of acellular alpha alpha -Hb on carbachol-induced relaxation of precontracted rabbit aorta segments. bullet , Untreated controls, n = 7; open circle , 0.5 mg/dl, n = 4; triangle , 2.5 mg/dl (n = 4); black-square, 5.0 mg/dl (n = 3). Each point represents mean ± SE.
[View Larger Version of this Image (21K GIF file)]

Fig. 3. Effect of stroma-free Hb on carbachol-induced relaxation of precontracted rabbit aorta segments. bullet , Untreated controls, n = 13; open circle , control repeat, n = 12; square , 0.5 mg/dl, n = 4; black-square, 1.0 mg/dl, n = 3; triangle , 2.5 mg/dl, n = 4; black-triangle, 5.0 mg/dl, n = 5. Each point represents mean ± SE.
[View Larger Version of this Image (27K GIF file)]

Substantially higher concentrations of liposome-encapsulated alpha alpha -Hb were required to inhibit carbachol-induced relaxation. Concentrations of 15, 30, and 60 mg/dl of encapsulated alpha alpha -Hb produced statistically significant inhibition of 22 (P < 0.05), 29 (P < 0.005), and 60% (P < 0.005), respectively, compared with the maximum response to carbachol (Fig. 4). The EC50 calculated from these data for encapsulated alpha alpha -Hb was 50 mg/dl. These results demonstrate that liposome encapsulation produced an attentuation of ~30-fold of the vasoconstrictor activity of alpha alpha -Hb to inhibit NO-mediated relaxation compared with the acellular SFHB or alpha alpha -Hb. In vessels exposed to both acellular and encapsulated alpha alpha -Hb, addition of a supramaximal concentration (10-5 M) of S-nitrosylpenacillamine (SNAP), an exogenous NO donor, overcame the Hb-induced inhibition of relaxation (Fig. 5). This suggests that the inhibition of vasorelaxation in this model is mediated by interactions of acellular or encapsulated Hb with NO.
Fig. 4. Effect of liposome-encapsulated alpha alpha -Hb on carbachol-induced relaxation of precontracted rabbit aorta segments. bullet , Untreated controls, n = 8; open circle , 15 mg/dl, n = 3;square , 30 mg/dl, n = 3; triangle , 60 mg/dl, n = 5. Each point represents mean ± SE.
[View Larger Version of this Image (24K GIF file)]

Fig. 5. Tensiogram of carbachol-induced relaxation after precontraction with norepinephrine-precontracted rabbit aorta segment and subsequent reversal of alpha alpha -Hb-induced inhibition by nitric oxide (NO) donor S-nitrosylpenacillamine (SNAP). A: cycle of contraction and relaxation by 10-7 M norepinephrine and increasing concentration of carbachol, respectively. B: addition of 10-5 M SNAP resulted in reversal of inhibition induced by 60 mg/dl encapsulated alpha alpha -Hb. C: addition of 10-7-10-5 M SNAP also resulted in reversal of inhibition induced by 1.0 mg/dl acellular alpha alpha -Hb.
[View Larger Version of this Image (14K GIF file)]

Contraction of electrically stimulated perfused rabbit ear arterial segments. A physiograph recording of the potentiation produced by acellular alpha alpha -Hb of electrically induced contraction of the perfused rabbit ear artery is shown in Fig. 6. The contractile amplitude increases dramatically over the concentration of 0.025-0.5 mg/dl compared with vessels perfused with vehicle buffer. Perfusion of alpha alpha -Hb at concentrations >0.5 mg/dl caused a direct contraction of three of six vessels without electrical stimulation. Encapsulated alpha alpha -Hb also increased the electrically stimulated contractile amplitude in a similar fashion but at a concentration nearly two orders of magnitude higher than acellular alpha alpha -Hb (0.5-62.5 mg/dl). Direct contraction of the vessel without electrical stimulation by encapsulated alpha alpha -Hb was observed in one of four vessels at a concentration of 62.5 mg/dl. The potentiation of the electrically stimulated contractile response produced with acellular and encapsulated alpha alpha -Hb is summarized in Fig. 7. Both preparations produced dose-dependent potentiation of contractile-response amplitude in this model. For purposes of comparison, the concentration required to produce a 150% increase over baseline contractile amplitude (EC150) was calculated for both Hb preparations. The EC150 for acellular and encapsulated alpha alpha -Hb was 0.23 and 13.7 mg/dl (P < 0.005), respectively, demonstrating a statistically significant 60-fold reduction in potency. These data demonstrate that encapsulation of alpha alpha -Hb attenuates the potentiation of the contractile responses in arterial vessels when compared with the acellular form.
Fig. 6. Physiograph recording of contractile response of isolated perfused rabbit ear artery to electrical stimulation and concentration-related enhancement of contractile amplitude produced by 0.01-0.5 mg/dl acellular alpha alpha -Hb.
[View Larger Version of this Image (9K GIF file)]

Fig. 7. Concentration-response curves of enhancement of electrical stimulation-induced contraction amplitude in perfused rabbit ear artery produced by acellular alpha alpha -Hb (bullet , n = 6) and encapsulated alpha alpha -Hb (open circle , n = 4). Each point represents mean ± SE.
[View Larger Version of this Image (19K GIF file)]

eNOS activity. The effect of acellular and liposome-encapsulated alpha alpha -Hb on eNOS activity was determined by measuring the conversion of [3H]arginine to [3H]citruline by enzyme isolated from bovine pulmonary artery endothelial cells. Concentrations of 0.05, 0.1, 0.5, 1.0, and 5.0 mg/dl of acellular Hb and concentrations of 2.5, 5, 10, 20, and 40 mg/dl of encapsulated alpha alpha -Hb had no effect on eNOS activity (data not shown).

[3H]Norepinephrine release from perfused rabbit ear artery. Acellular alpha alpha -Hb also did not affect the release of norepinephrine from the perfused electrically stimulated rabbit ear artery (Fig. 8). Control stimulated-to-basal [3H]norepinephrine release ratios were 3.0 ± 0.07, 2.9 ± 0.09, and 3.0 ± 0.1 for the three stimulations preceding the introduction of acellular alpha alpha -Hb. Stimulated-to-basal [3H]norepinephrine release ratios after concentrations of 0.1, 0.5, and 2.0 mg/dl of acellular alpha alpha -Hb were 3.2 ± 0.08, 3.3 ± 0.1, and 3.0 ± 0.3, respectively. Rauwolscine increased the stimulated to basal release ratio to 9.9 ± 2.1 at a concentration of 100 nM.
Fig. 8. Effect of acellular alpha alpha -Hb on release of [3H]norepinephrine (NE) from perfused rabbit ear artery. Release is expressed as ratio of 3H counts collected during stimulation to counts obtained before stimulation. Solid bars, stimulated-to-basal release ratio for 3 stimulations before introduction of alpha alpha -Hb; gray bars, effect of increasing concentrations of alpha alpha -Hb on stimulated/basal release ratio; open bar, potentiation of [3H]NE release produced by rauwolscine (100 nM). Each bar represents mean ± SE of 4 tissues.
[View Larger Version of this Image (18K GIF file)]

Kinetics of alpha alpha -Hb-NO and encapsulated alpha alpha -Hb-NO interactions. Stopped-flow kinetic studies with NO and Hb demonstrated that NO conversion of alpha alpha -oxyHb to alpha alpha -metHb (indicated by an absorbance peak at 630 nm) was complete within the 2-ms mixing time of the apparatus (Fig. 9, A and C). The NO-induced oxidation occurred with both alpha alpha -Hb and encapsulated alpha alpha -Hb solutions. Subsequent binding of NO to ferric heme (indicated by an increase in absorbance at 563 nm) was complete in 300 ms with both preparations (Fig. 9, B and D).
Fig. 9. Stopped-flow kinetics of NO with acellular alpha alpha -Hb (A and B) or encapsulated alpha alpha -Hb (C and D). A: rapid conversion (<2 ms) of alpha alpha -Hb+2O2 to alpha alpha -Hb+3 (alpha alpha -metHb) by exposure to NO. B: increased absorbance at 563 nm over time as metHB is converted to NO-Hb (300 ms). C: rapid conversion (<2 ms) of encapsulated alpha alpha -Hb+2O2 to encapsulated alpha alpha -Hb+3O2 by exposure to NO. Consecutive 1-ms spectral scans are recorded over light-scattering background. D: increase in absorbance at 563 nm as encapsulated metHb is converted to encapsulated NO-Hb (300 ms).
[View Larger Version of this Image (26K GIF file)]

DISCUSSION

The vasoconstrictor activity of acellular Hb has been investigated in a number of in vitro and in vivo animal models. Early studies suggested that the presence of lipophilic and nonlipophilic components in Hb preparations were responsible for vasoconstriction (13, 15). Improvements in Hb-manufacturing processes have eliminated contaminants from Hb solutions and have allowed for a more direct investigation into the vasoconstrictor activity of the Hb molecule. Hb-induced vasoconstriction in vitro has been shown to be dose dependent and to vary with species and vessel origin (51). SFHb-induced vasoconstriction was demonstrated in cerebral arteries of the monkey and dog in models of subarachnoid hemorrhage and delayed cerebral vasospasm. Vasoconstrictor activity of SFHb was markedly attenuated by denuding the endothelium and treatment with indomethacin or aspirin (cyclooxygenase inhibitors), diphloretin phosphate (a prostaglandin-receptor antagonist), and imidazolyl(methyl)phenyl-2-propenoic acid (a thromboxane-synthesis inhibitor) (51). On the basis of these findings, it was suggested that the mechanism of the vasoconstrictor response of oxyHb was related to the release of arachidonic acid metabolites and prostaglandins from the endothelium and not solely to an endothelium-derived relaxation factor-related mechanism. In similar studies, the vasoconstrictor activity of SFHb in isolated dog basilar arteries was not altered by denuding the vessels (9).

Additional studies of purified alpha alpha -Hb preparations have focused attention on the release of vasoactive peptides, such as endothelin (ET) or other eicosanoids, and on adrenergic mechanisms of action (17, 46). Pretreatment with phosphoramidon (a metalloproteinase inhibitor of Big ET conversion to biologically active ET) was shown to attenuate the pressor response in rats after the infusion of a preparation of alpha alpha -Hb similar to that used in the present studies. Pressor responses to alpha -adrenoceptor agonists were observed to be enhanced in the rat after the administration of alpha alpha -Hb (47, 48). It has been suggested that alpha alpha -Hb may sensitize alpha 1- and alpha 2-adrenoceptors because the enhancement of norepinephrine-, phenylephrine-, or clonidine-induced pressor responses was inhibited by standard alpha -adrenoceptor antagonists (48).

Although several mechanisms may contribute to the vasoconstrictor activity of Hb, previous reports implicate the binding of NO as the major contributor to this action. The vasoconstrictor activity of Hb in isolated vessel segments is endothelium dependent and can be blocked by inhibiting NO synthase with agents such as nitro-L-arginine methyl ester or by inhibiting guanylyl cyclase with methylene blue (9, 14, 26, 32). Vasoconstrictor activity of Hb is also blocked by inhibitors of NO synthase and can be reversed by the administration of L-arginine, the substrate for NO synthase (32, 46). The administration of cyanometHb, which is unable to interact with NO, does not evoke a hypertensive response (18, 24). Thus, the binding of NO by Hb effectively removes a major vasodilatory component of vascular tone and may be responsible for the observed Hb-induced constriction.

In our studies, encapsulation in liposomes was found to significantly reduce the vasoconstrictor activity of Hb, ~30-fold in the rabbit aortic segment and 50-fold in the electrically stimulated ear artery. Although other mechanisms cannot be definitively ruled out, the mechanism of vasoconstrictor action for both preparations most likely involves NO binding. Complete vessel relaxation was obtained in aortic segments by the addition of SNAP, an NO donor, indicating that guanosine 3',5'-cyclic monophosphate (cGMP)-mediated vasorelaxation within the vascular smooth muscle cell was not affected by either acellular or liposome-encapsulated Hb preparation. Previous studies with this model also demonstrate that vasoconstriction is abolished by tetrodotoxin and is inhibited in a concentration-dependent manner by the alpha 1-adrenoceptor antagonist prazosin and is enhanced by rauwolscine (1, 55). This indicates that the contractile response is mediated by alpha 1-adrenoceptors activated by norepinephrine released from sympathetic nerve terminals. We demonstrated that the Hb vasoactivity of acellular and encapsulated Hb in this model is not due to differences in norepinephrine release, because alpha alpha -Hb did not affect the release of [3H]norepinephrine. In addition, we can rule out the hypothesis that the differences in the vasoconstrictor activity of acellular and encapsulated Hb are due to a direct effect on NOS activity, as neither acellular nor encapsulated Hb was found to have an inhibitory effect on eNOS activity.

Because Hb is a potent ligand for NO, we have explored whether differences in the kinetics of NO binding in aqueous solutions of acellular and encapsulated Hb could account for the differences in vascular reactivity. Previous spectroscopic studies of Hb-NO ligand interactions have shown that the heme group acts as a NO sink in a diffusion-limited binding reaction that occurs at equal rates to Hb subunits and favors the T quaternary structure (19, 29). Stopped-flow kinetic measurements of Hb-NO binding reveal that the NO-induced conversion of oxyHb to metHb for both acellular alpha alpha -Hb and encapsulated alpha alpha -Hb is rapid (<2 ms). Subsequent reaction kinetics of NO-metHb for either acellular or liposome-encapsulated met-alpha alpha -Hb are similar, indicating that the liposome bilayer does not present a significant diffusion barrier to NO. This suggests that the attenuated vasoconstrictor activities of encapsulated Hb are not related to inherent differences in NO-binding kinetics between acellular and encapsulated forms.

The reduced vasoconstrictor activity of encapsulated Hb in these isolated vessel models may correlate with the lack of hypertensive response observed after the in vivo application of encapsulated Hb in exchange-transfused and hemorrhagic-shock models (16, 38-40). The mechanisms of vasoconstriction of acellular and encapsulated alpha alpha -Hb in these models are not clear. We suggest that the differences in the vasoconstrictor activity between acellular and encapsulated Hb are a result of differences in the spatial distribution of Hb in the vasculature. Differences in the flow properties of the two preparations based on their size (and effective molecular weight) would result in the acellular Hb transitting closer to the surface of the endothelium on the luminal side, shortening the diffusion length of Hb-NO binding, and creating a larger concentration gradient of NO away from the smooth muscle junction. This contrasts with the larger liposome-encapsulated Hb (0.2 µm) that would transit farther away from the luminal endothelial surface, increasing the diffusion length for Hb-NO binding and decreasing the concentration gradient of NO away from the smooth muscle junction and cGMP-induced vasorelaxation.

Alternatively, the differences in acellular and encapsulated Hb vasoactivity could be related to differences in spatial distribution in the subendothelial compartment where Hb would encounter and bind NO before it reached the vascular smooth muscle. In support of this, it was recently reported that acellular Hb, but not encapsulated Hb, could pass through endothelial junctions in an in vitro model of the endothelial cell layer (22). Biodistribution studies of alpha alpha -Hb in rats are also consistent with the distribution of free Hb into compartments not accessible to the encapsulated form. The vascular persistence of alpha alpha -Hb shows a 4- to 6-h half-life at clinically relevant doses (30-50% exchange transfusion) with a considerable amount (40%) unaccounted for in the vascular pool or associated organs. This was attributed to tissue extravasation (21). In contrast, encapsulated Hb has shown 18- to 20-h vascular persistence half-life with 97% of the encapsulated Hb accounted for in the vascular pool or organs of the reticuloendothelial system (44). These data strongly suggest that acellular Hb may have access to NO at both the luminal and subendothelial sites, whereas the encapsulated form, because of its large size, may encounter NO only at the luminal site. This does not rule out other mechanisms that may explain differences in vasoconstrictor activity between acellular and encapsulated Hb, and definitive studies that examine extravasation of Hb are warranted. Other possible mechanisms of acellular- and encapsulated-Hb vasoactivity include differences in interactions with adrenergic receptors or the amount of catalytically active iron or heme available to the vascular endothelium that has been shown to cause cellular damage by upregulating heme oxygenase and ferritin (5).

Vasoconstriction has emerged as a significant concern in the clinical use of Hb-based blood substitutes. A preparation shown to have reduced vasoconstrictor liability may possess therapeutic advantages for certain clinical indications. The present study evaluates the fundamental differences in the vasoconstrictor activity of Hb and suggests that Hb presentation (by encapsulation) to the vasculature may alter the vasoconstrictor response. We have determined the effects of these preparations on vascular tone in two models: 1) an in vitro model of NO-mediated vasorelaxation (precontracted rabbit aorta) and 2) a model of vasoconstriction (perfused rabbit ear artery). The demonstrated attenuation of vasoconstrictor activity by the encapsulation of Hb may extend the clinical utility of Hb-based red blood cell substitutes as well as provide a useful model for pharmacological interventions in the control of vascular tone.

ACKNOWLEDGEMENTS

We thank Richard O. Cliff, Victoria Kwasiborski, Chris Driscoll, and Lloyd Lippert for technical assistance.

FOOTNOTES

   We gratefully acknowledge the financial support of the US Naval Medical Research and Development Command, the Office of Naval Research, and the US Army Medical Research and Development Command.

   The opinions and assertions herein are the private ones of the authors and are not to be construed as official policy, or reflecting the views of the US Department of Defense.

Address for reprint requests: A. S. Rudolph, Center for Bio/Molecular Science and Engineering, Code 6910, Naval Research Laboratory, Washington, DC 20375-5348 (E-mail: arudolph{at}cbmse.nrl.navy.mil).

Received 16 April 1996; accepted in final form 29 January 1997.

REFERENCES

1. Abrahamson, J., and O. A. Nedergaard. Presynaptic modulation by adrenaline of 3H-noradrenaline release in rabbit ear artery. Pharmacology 42: 79-85, 1991. [Medline]
2. Amberson, W. R., J. Flexner, F. R. Steggerda, A. G. Mulder, M. J. Tendler, D. S. Pandratz, and E. P. Lan. On the use of Ringer-Locke solutions containing hemoglobin as a substitute for normal blood in mammals. J. Cell. Comp. Physiol. 5: 359-382, 1934.
3. Amberson, W. R., J. J. Jennings, and C. M. Rhode. Clinical experience with hemoglobin-saline solutions. J. Appl. Physiol. 1: 156-169, 1949.
4. Anand, N., and W. G. Paterson. Role of nitric oxide in esophageal peristalsis. Am. J. Physiol. 266 (Gastrointest. Liver Physiol. 29): G123-G131, 1994 . [Abstract/Free Full Text]
5. Balla, J., K. A. Nath, G. Balla, M. B. Juckett, H. S. Jacob, and G. M. Vercellotti. Endothelial cell heme oxygenase and ferritin induction in rat lungs by hemoglobin in vivo. Am. J. Physiol. 268 (Lung Cell. Mol. Physiol. 12): L321-L327, 1995 . [Abstract/Free Full Text]
6. Bredt, D. S., and S. H. Snyder. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc. Natl. Acad. Sci. USA 86: 9030-9033, 1989 . [Abstract/Free Full Text]
7. Chang, T. M. S. Semi-permeable microcapsules. Science 146: 524-525, 1964. [Abstract/Free Full Text]
8. Collins, P., J. Burman, H. I. Chung, and K. Fox. Hemoglobin inhibits endothelium, dependent relaxation to acetylcholine in human coronary arteries in vivo. Circulation 87: 80-85, 1993 . [Abstract/Free Full Text]
9. Connor, H. E., and W. Feniul. Role of endothelium in hemoglobin induced contraction of dog basilar artery. Eur. J. Pharmacol. 140: 105-108, 1987 . [Medline]
10. Djordjevich, L., and I. F. Miller. Synthetic erythrocytes from lipid-encapsulated hemoglobin. Exp. Hematol. 8: 584-592, 1980 . [Medline]
11. Dodd, R. Y. The risk of transfusion-transmitted infection. N. Engl. J. Med. 327: 419-421, 1992 . [Medline]
12. Farmer, M. C., A. S. Rudolph, K. D. Vandegriff, M. D. Hayre, S. A. Bayne, and S. A. Johnson. Liposome-encapsulated hemoglobin: oxygen binding properties and respiratory function. Biomat. Artif. Cells Artif. Organs 16: 289-299, 1988 .
13. Feola, M., J. Simoni, P. C. Canizaro, R. Tran, and G. Raschbaum. Mechanisms of toxicity of hemoglobin solutions. Surg. Gynecol. Obstet. 166: 211, 1988 . [Medline]
14. Furchgott, R. F., and J. V. Zawadzki. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373-376, 1980 . [Medline]
15. Gilroy, D., C. Shaw, E. Parry, and W. Odling-Smee. Detection of a vasoconstrictor factor in stroma-free hemoglobin solutions. J. Trauma 28: 1312-1316, 1989.
16. Goins, B., R. Klipper, J. Sanders, R. O. Cliff, A. S. Rudolph, and W. T. Phillips. Physiological responses, organ distribution, and circulation kinetics in anesthetized rats after hypovolemic exchange transfusion with technetium-99m-labeled liposome-encapsulated hemoglobin. Shock 4: 121-130, 1995 . [Medline]
17. Gulati, A., and S. Rebello. Role of adrenergic mechanisms in the pressor effect of diaspirin cross-linked hemoglobin. J. Lab. Clin. Med. 124: 125-133, 1994 . [Medline]
18. Hess, J. R., V. W. MacDonald, and W. W. Brinkley. Systemic and pulmonary hypertension after resuscitation with cell-free hemoglobin. J. Appl. Physiol. 74: 1769-1778, 1993 [Abstract/Free Full Text] .
19. Hille, R., G. Palmer, and J. S. Olson. Chain equivalence in reaction of nitric oxide with hemoglobin. J. Biol. Chem. 252: 403-405, 1977 . [Abstract/Free Full Text]
20. Hunt, C. A., R. R. Burnette, R. D. MacGregor, A. Strubbe, D. T. Lau, N. Taylor, and H. Kawada. Synthesis and evaluation of a prototypal artificial red cell. Science 230: 1165-1168, 1985 . [Abstract/Free Full Text]
21. Keipert, P. E., and L. Triner. Catabolism and excretion of cross-linked hemoglobin. In: The Red Cell: 7th Ann Arbor Conf. New York: Liss, 1989, p. 383-405.
22. Kobayashi, Y., K. Ikebuchi, and S. Sekiguchi. Comparison of endothelial cell permeability of acellular and cellular hemoglobin. Artif. Cells Blood Sub. Immobil. Biotech. 24: 364, 1996.
23. Lasic, D. D., and D. Papahadjopoulos. Liposomes revisited. Science 267: 1275-1276, 1995 . [Free Full Text]
24. MacDonald, V. W., and R. Motterlini. Cell-free hemoglobin potentiates acetylcholine-induced coronary vasoconstriction in rabbit hearts. J. Appl. Physiol. 75: 2224-2233, 1993. [Abstract/Free Full Text]
25. Martin, W., J. A. Smith, and D. G. White. The mechanism by which hemoglobin inhibits the relaxation of rabbit aorta induced by nitrovasodilators, nitric oxide, or bovine retractor penis inhibitory factor. Br. J. Pharmacol. 89: 563-571, 1986 . [Medline]
26. Martin, W., G. M. Villani, J. Designaro, and F. Furchgott. Selective blockade of endothelium-dependent glycerol trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta. J. Pharmacol. Exp. Ther. 232: 708-716, 1985 . [Abstract/Free Full Text]
27. Marwick, C. More than a trickle of interest in blood substitutes. J. Am. Med. Assoc. 271: 895, 1994 . [Medline]
28. Matheson, I. B. C. The method of successful integration: a general technique for recasting kinetic equations in a readily soluble form which is linear in the coefficients and sufficiently rapid for real time instrumental use. Anal. Instrum. 16: 345-373, 1987.
29. Morris, R. J., and Q. H. Gibson. The role of diffusion in limiting the rate of ligand binding to hemoglobin. J. Biol. Chem. 255: 8050-8053, 1980 . [Abstract/Free Full Text]
30. Moss, G. S., R. DeWoskin, A. L. Rosen, H. Levine, and C. K. Palani. Transport of oxygen and carbon dioxide by hemoglobin-saline solution in the red cell free primate. Surg. Gynecol. Obstet. 142: 357-362, 1976 . [Medline]
31. Moss, G. S., S. A. Gould, A. L. Rosen, L. R. Sehgal, and H. L. Sehgal. Results of the first clinical trial with a polymerized hemoglobin solution (Abstract). Biomat. Artif. Cells Artif. Organs 17: 633, 1989.
32. Muldoon, S., J. Hart, and M. Ledvina. DCLHb-induced contractions of isolated blood vessels are dependent on nitric oxide production. Artif. Cells Blood Sub. Immobil. Biotech. 24: 392-398, 1996.
33. Murray, J. A., A. Ledlow, J. Launspach, D. Evans, M. Loveday, and J. L. Conklind. The effects of recombinant human hemoglobin on esophageal motor function in humans. Gastroenterology 109: 1241-1248, 1995. [Medline]
34. Ning, J., L. M. Peterson, P. J. Anderson, and G. P. Biro. Systemic hemodynamic and renal effects of unmodified human SFHS in dogs. Artif. Cells Immob. Biotech. 20: 723-727, 1992.
35. Olson, J. S. Stopped-flow, rapid mixing measurements of ligand binding to hemoglobin and red cells. In: Methods in Enzymology, edited by E. Antonini, L. Rossi-Bernardi, and E. Chiancone. New York: Academic, 1981, vol. 76, p. 631-651.
36. Przybelski, J., D. S. Malcolm, D. G. Burris, and R. M. Winslow. Cross-linked hemoglobin as a resuscitative fluid after hemorrhage in the rat. J. Lab. Clin. Med. 117: 143-151, 1991. [Medline]
37. Rabinovici, R., A. S. Rudolph, and G. Feuerstein. Characterization of hemodynamic, hematological, and biochemical responses to administration of liposome-encapsulated hemoglobin in the conscious, freely moving rat. Circ. Shock 29: 115-132, 1989 . [Medline]
38. Rabinovici, R., A. S. Rudolph, and G. Feuerstein. Improved biological properties of synthetic distearoyl phosphatidyl choline-based liposome in the conscious rat. Circ. Shock 30: 207-219, 1990 . [Medline]
39. Rabinovici, R., A. S. Rudolph, F. S. Ligler, E. F. Smith, and G. Feuerstein. Biological responses to exchange transfusion with liposome encapsulated hemoglobin. Circ. Shock 37: 124-133, 1992 . [Medline]
40. Rabinovici, R., A. S. Rudolph, J. Vernick, and G. Feuerstein. A new salutary resuscitative fluid: liposome encapsulated hemoglobin/hypertonic saline solution. J. Trauma 35: 121-127, 1993 . [Medline]
41. Rabinovici, R., A. S. Rudolph, T. L. Yue, and G. Feuerstein. Biological responses to liposome-encapsulated hemoglobin (LEH) are improved by a PAF antagonist. Circ. Shock 31: 431-445, 1990 . [Medline]
42. Rioux, F., E. Petitclerc, R. Audet, G. Drapeau, R. M. Fielding, and F. Marceau. Recombinant human hemoglobin inhibits both constitutive and cytokine-induced nitric oxide-mediated relaxation of rabbit isolated aortic rings. J. Cardiovasc. Pharmacol. 24: 229-237, 1994 . [Medline]
43. Rudolph, A. S. The freeze-dried preservation of liposome encapsulated hemoglobin: a potential blood substitute. Cryobiology 25: 277-284, 1988 . [Medline]
44. Rudolph, A. S., R. W. Klipper, B. Goins, and W. T. Phillips. In vivo biodistribution of a radiolabeled blood substitute: 99mTc-labeled liposome encapsulated hemoglobin in an anesthetized rabbit. Proc. Natl. Acad. Sci. USA 88: 10976-10980, 1991 . [Abstract/Free Full Text]
45. Savitsky, J. P., J. Doczi, J. Black, and J. D. Arnold. A clinical safety trial of stroma-free hemoglobin. Clin. Pharmacol. Ther. 23: 73-80, 1978 . [Medline]
46. Schultz, S. C., B. Grady, F. Cole, I. Hamilton, K. Burhop, and D. Malcolm. A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J. Lab. Clin. Med. 122: 301-308, 1993 . [Medline]
47. Sharma, A. C., and A. Gulati. Effect of diaspirin cross-linked hemoglobin and norepinephrine on systemic hemodynamics and regional circulation in rats. J. Lab. Clin. Med. 123: 299-308, 1994 . [Medline]
48. Sharma, A., and A. Gulati. Yohimbine modulates diaspirin cross-linked hemoglobin-induced systemic hemodynamics and regional circulatory effects. Crit. Care Med. 23: 1-11, 1995. [Medline]
49. Steinsland, O. S., R. F. Furchgott, and R. Kirpekar. Biphasic vasoconstriction of rabbit ear artery. Circ. Res. 32: 49-58, 1973 . [Abstract/Free Full Text]
50. Thompson, A., A. E. McGarry, V. Valeru, and L. Leiberthal. Stroma-free hemoglobin increases blood pressure and GFR in the hypotensive rat: role of nitric oxide. J. Appl. Physiol. 77: 2348-2354, 1994 [Abstract/Free Full Text] .
51. Toda, N. Mechanisms of contracting action of oxyhemoglobin in isolated monkey and dog cerebral arteries. Am. J. Physiol. 259 (Heart Circ. Physiol. 28): H57-H63, 1990.
52. Tsai, A., H. Kerger, and M. Intaglietta. Microcirculatory consequences of blood substitutes with hemoglobin. In: Blood Substitutes: Physiological Basis of Efficacy. Boston, MA: Birkhauser, 1995, p. 155-175.
53. Winslow, R. M. The toxicity of hemoglobin. In: The Hemoglobin Based Red Cell Substitutes. Baltimore, MD: Johns Hopkins Univ. Press, 1992, p. 136-162.
54. Winslow, R. M., and K. W. Chapman. Pilot scale preparation of hemoglobin solutions. In: Methods of Enzymology: Hemoglobins B, Biochemical and Analytical Methods. San Diego, CA: Academic, 1994, vol. 231, p. 3-16.
55. Wright, I. K., N. A. Blaylock, D. A. Kendall, and V. G. Wilson. The relationship between density of alpha-adrenoceptor binding sites and contractile responses in several porcine isolated blood vessels. Br. J. Pharmacol. 114: 678-688, 1995 . [Medline]
56. Zuck, T. F., and J. G. Riess. Current status of injectable oxygen carriers. Crit. Rev. Clin. Lab. Sci. 31: 295-324, 1994 . [Medline]


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Sakai, A. Sato, K. Masuda, S. Takeoka, and E. Tsuchida
Encapsulation of Concentrated Hemoglobin Solution in Phospholipid Vesicles Retards the Reaction with NO, but Not CO, by Intracellular Diffusion Barrier
J. Biol. Chem., January 18, 2008; 283(3): 1508 - 1517.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
V. Awasthi, S.-H. Yee, P. Jerabek, B. Goins, and W. T. Phillips
Cerebral oxygen delivery by liposome-encapsulated hemoglobin: a positron-emission tomographic evaluation in a rat model of hemorrhagic shock
J Appl Physiol, July 1, 2007; 103(1): 28 - 38.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
H. Sakai, H. Hara, M. Yuasa, A. G. Tsai, S. Takeoka, E. Tsuchida, and M. Intaglietta
Molecular dimensions of Hb-based O2 carriers determine constriction of resistance arteries and hypertension
Am J Physiol Heart Circ Physiol, September 1, 2000; 279(3): H908 - H915.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. Liu, M. J. S. Miller, M. S. Joshi, H. Sadowska-Krowicka, D. A. Clark, and J. R. Lancaster Jr.
Diffusion-limited Reaction of Free Nitric Oxide with Erythrocytes
J. Biol. Chem., July 24, 1998; 273(30): 18709 - 18713.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rudolph, A. S.
Right arrow Articles by Feuerstein, G.